Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

CLS and University Hospital Magdeburg launch clinical trial regarding focal laser ablation treatment of localized prostate cancer

Lund, Sweden, 12 October 2020 – Clinical Laserthermia Systems (publ)  and Otto-von-Guericke-University Magdeburg, Medical faculty  are entering into an agreement regarding an Investigator Initiated Trial (IIT) targeting MRI-Ultrasound fusion guided focal laser ablation treatment of prostate cancer, up to Gleason 7a (3+4), using CLS’ TRANBERG® Thermal Therapy System  for high-precision, minimally invasive interventions. Previously this year CLS announced that

C-RAD Web Presentation Interim Report Q3 2020

Invitation to join the presentation of the C-RAD Q3 interim report Date: Thursday October 22, 2020 / kl. 11:00 CET Venue: Online Presentation Topic: C-RAD Interim Report Q3 2020 Procedure: Please register online through the website:   https://attendee.gotowebinar.com/register/7890477381628997900 After the registration, you will receive a confirmation via email. A recording of the presentation will be made accessible on the C-RAD website after the presentation. About C-RAD C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly

Change in Atlas Copco AB’s Nomination Committee for the Annual General Meeting 2021

Stockholm, Sweden, October 12, 2020: Due to changes in ownership in Atlas Copco AB, and in accordance with the instructions for the Nomination Committee decided by the Annual General Meeting, Handelsbanken Fonder AB will replace SEB Investment Management AB.Representatives: Petra Hedengran, Investor AB (chair)Jan Andersson, Swedbank Robur fundsMikael Wiberg, AlectaHelen Fasth Gillstedt, Handelsbanken Fonder ABHans Stråberg, Chair of the Board, Atlas Copco ABThe Annual General Meeting of Atlas Copco AB will be held on April 27, 2021, at 16.00.Shareholders who wish to submit

CLS and University Hospital Magdeburg launch clinical trial regarding focal laser ablation treatment of localized prostate cancer

Irvine, CA, October 12, 2020 – Clinical Laserthermia Systems (publ)  and Otto-von-Guericke-University Magdeburg, Medical faculty  are entering into an agreement regarding an Investigator Initiated Trial (IIT) targeting MRI-Ultrasound, fusion-guided focal laser ablation treatment of prostate cancer, up to Gleason 7a (3+4), using CLS’ TRANBERG® Thermal Therapy System  for high-precision, minimally invasive interventions. Previously this year, CLS announced that

Change in Epiroc AB’s Nomination Committee for the Annual General Meeting 2021

Stockholm, Sweden: Epiroc AB’s Nomination Committee for the Annual General Meeting 2021, which was originally announced on October 5, 2020, has changed.Due to changes in the ownership of Epiroc AB and according to rules set by the Annual General Meeting for the Nomination Committee, Handelsbanken funds will replace SEB Investment Management. Handelsbanken funds’ representative is Helen Fasth Gillstedt.   The following persons will form the Nomination Committee for the Annual General Meeting 2021. Petra Hedengran – Investor AB (Chair)Mikael Wiberg – AlectaHelen Fasth Gillstedt –

Cancer leader City of Hope selects DigniCap for community network in California

Dignitana AB  today announces that City of Hope  has selected DigniCap as the scalp cooling provider of choice for its community network of 12 cancer treatment centers in California. The DigniCap[®] Scalp Cooling System minimizes hair loss from chemotherapy in patients with solid tumors.City of Hope National Medical Center in Duarte, California has used DigniCap since 2016 and in March 2020 DigniCap was installed at the newly constructed Newport Beach location. DigniCap will be available in City of Hope’s South Pasadena and

More stroke patients can be saved with CT scan in helicopter

When someone suffers a stroke, rapid diagnosis and correct treatment are absolutely crucial. But to be able to make the right diagnosis, the patient needs a CT scan, a form of medical imaging procedure. Norsk Luftambulanse, the Norwegian Air Ambulance Foundation, has demonstrated through research studies that pre-hospital diagnosis and treatment are possible. They have now involved Semcon in a project which aims initially to prove that it is possible to install a CT scanner in a helicopter ambulance.Stroke is one of the most expensive physical conditions by far, and the right care being

Redwood Pharma to present at Aktiespararnas Stora Aktiedagen Digitalt in Stockholm on November 30, 2020

On November 30, CEO Martin Vidaeus from Redwood Pharma will present at Aktiespararnas Stora Aktiedagen Digitalt (www.aktiespararna.se/aktiviteter/evenemang) in Stockholm. The presentation will be in English. The program and registration for the event can be found on the event’s website, where a link to the live streamed broadcast of the presentation will also be available on November 30. The company will present: · An update of the company’s operations and milestones · An update of RP101 and its development · An introduction to the new RP501 dry eye program · Plans for the

Neles Corporation comments on Valmet Corporation's merger proposal

Neles Corporation Stock Exchange Release 12 October 2020 at 9:30 a.m.Neles Corporation ("Neles") refers to the stock exchange release published by it on 29 September 2020 regarding Valmet Corporation's ("Valmet") proposal to Neles' Board of Directors to start discussions on a potential merger (the "Proposal"). The Board of Directors of Neles has carefully assessed the Proposal and, taking into account that the public tender offer by Alfa Laval AB (publ) (the "Tender Offer") is expected to expire on 22 October 2020, has urgently sought clarifying information on the Proposal. However, as the

The Covid-19 pandemic is expected to further affect RhoVac’s clinical phase IIb study

Lund, October 12, 2020. RhoVac AB (“RhoVac”) announces today that the company's clinical phase IIb study in prostate cancer, a multi-center study with the designation RhoVac-002 (“BRaVac”), is expected to be further delayed due to the prevailing Covid-19 pandemic. The recruitment rate in September now indicates full recruitment in Q2 2021. To reduce the effect of the delays caused by the pandemic, the number of clinics will be increased. The study is still expected to be carried out with existing funding.BRaVac is a randomized, placebo-controlled and double-blind study, with the primary

State Street and SimCorp Announce Intended Business Partnership, with Front-to-Back Investment Outsourcing Solution for EMEA Insurers

Strategic Business Partnership Demonstrates State Street and SimCorp’s Commitment to Insurance Clients in EMEA, with a Complete Front-to-Back Outsourcing Solution through the State StreetAlpha[SM]  Platform October 12, 2020 —State Street Corporation  (NYSE: STT) and investment management solutions and service provider, SimCorp  (OMXC25: SIM), today announced their intent to form a business partnership to provide a premier, fully integrated, front-to-back investment outsourcing solution for insurance firms in Europe, Middle

Leading Scandinavian IT Company selects Zalaris to deliver Multi-Country Payroll for their operations in Denmark, Sweden, and Norway

Zalaris ASA, a leading provider of SaaS-based Payroll and HR services, has signed a five-year agreement with one of the fastest growing IT companies in Scandinavia.As part of the agreement, Zalaris will implement outsourced Managed Payroll services for the company’s 1.200 employees in Denmark, Sweden, and Norway. The services will be powered by Zalaris’ proven Multi-Country Cloud solution for payroll, with an employee portal and mobile self-services for HR professionals, managers and employees. The solution will be integrated with the customer’s global HR solution to support one way of

Sivers IMA wins SEK4m order for new project with existing Fortune 100 customer

KISTA, Sweden, 12[th] October, 2020 - Sivers IMA Holding AB (Nasdaq First North Growth Market: SIVE) today announced that its subsidiary, CST Global, has received an order worth approximately SEK4m for a new project from one of its established, Fortune 100 customers.The order covers design, development and supply of semiconductor laser prototype devices for use in advanced, optical sensing applications. The order comes in addition to existing framework orders from the same customer and will be completed and billed during 2020. Thus, this Fortune 100 customer has now placed orders at Sivers

Nyfosa has acquired a property at a total value of approximately MSEK 65

Nyfosa has acquired an office property in Örnsköldsvik at a value of approximately MSEK 65, which complements Nyfosa's existing portfolio in the area with strong cash flows.The acquired property Köpmannen 1 in Örnsköldsvik comprises an area of approximately 7 thousand square meters consisting of mainly offices with a rental value of approximately MSEK 8. The tenants include Örnsköldsvik Municipality, Medborgarskolan, ABB, Nordic Wellness and Euro Accident. The average contract period is 2.0 years with an occupancy rate of 86 percent. Closing date for the property was October 5, 2020.

Elkem receives Enova financial support for planning the battery materials industrial plant

Elkem has received NOK 10 million in financial support from Enova to fund the initial planning of the potential large-scale battery materials plant in Norway, named Northern Recharge. The project aims to supply the fast-growing battery industry through a competitive production process and make batteries greener with lower CO2 emissions.“A positive investment decision requires competitive public support mechanisms and supportive government policies. Elkem is also inviting industrial and financial partners to participate. Securing this initial support from Enova is an important step as we

With the priority review underway at FDA, Oncopeptides moves forward with intent to file for conditional approval of melflufen with EMA

STOCKHOLM — October 12, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has informed the European Medicines Agency, EMA, about its intention to submit an application for a conditional marketing authorization of melflufen (INN melphalan flufenamide) in the EU, based on the pivotal phase 2 HORIZON study in relapsed refractory multiple myeloma (RRMM).The decision to submit an application for conditional approval has been grounded on an in-depth analysis of the regulatory environment and is endorsed by key opinion leaders in the EU. Previously the Company

Issue of Equity

12 October 2020  Independent Oil and Gas plc Issue of New Shares and PDMR Shareholding  Independent Oil and Gas plc ("IOG" or "the Company"), (AIM: IOG.L), the development and production company focused on becoming a substantial UK gas producer, has today issued a total of 126,497 ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares"). On 9 October 2020, a notice was submitted by James Chance, a PDMR of the Company, to exercise 126,497 options over Ordinary Shares pursuant to a Salary Sacrifice Share Option agreement dated 6 October 2020 (the "Exercise"

COVID-19 antibodies advance and get US funding

9 October 2020 21:30 BST COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442rapidly advances into Phase III clinical trials Two trials of AZD7442 will enrol over 6,000 adults for the prevention of COVID-19 withadditional trials enrolling ~4,000 adults for the treatment of SARS-CoV-2 infections US Government to invest ~$486m for development and supply of up to 100,000 doses and can acquire another one million doses AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in

English version of PR published 20201012 at 07.33AM     SynAct Pharma completes part 1 of clinical phase II study with AP1189 in Rheumatoid Arthritis

SynAct Pharma AB ("SynAct") today announced that dosing of the leading candidate drug AP1189 was successfully completed in the second cohort (100 mg dose level) in part 1 of the company’s Phase IIa study in patients with Rheumatoid Arthritis (RA) with high disease activity.A data review on blinded non-validated data from 15 patients in the cohort of 100 mg dosing suggests that the compound is safe and well tolerated and shows that two thirds of the patients (10/15 patients) had a reduction in disease activity from severe to moderate or low disease activity during the 4 weeks treatment

SimCorp EMEA Signs non-binding Term Sheet with State Street Bank International GmbH

Company Announcement no. 38/2020 SimCorp EMEA and its current client State Street Bank International GmbH have today signed a non-binding Term Sheet setting out the main terms for entering into a strategic business partnership between the parties. The intention being to form a business partnership to provide a premier, fully integrated, front-to-back investment outsourcing solution for insurance firms in Europe, Middle East and Africa (EMEA). If and when the Term Sheet translates into a final strategic agreement, such agreement will become a "large contract" and SimCorp will disclose

Tokmanni’s financial information and Annual General Meeting in 2021

Tokmanni Group Corporation     Stock exchange release     12 October 2020 at 8:30 a.m.Tokmanni Group Corporation will publish its Financial Statement Release, Half Year Financial Report and two Business Reviews during 2021 as follows: 12 February 2021: Financial Statements Review for 202029 April 2021: Business Review for January-March 202129 July 2021: Half Year Financial Review for January-June 202129 October 2021: Business Review for January-September 2021 The 2020 Report by the Board of Directors and Financial Statements will be published during week 8. Tokmanni's Annual

Nomination Committee appointed for the Annual General Meeting 2021

The Nomination Committee ahead of the 2021 consists of: · Erik Malmberg, Actor SCA, Chair of the Nomination Committee · Carl Gustafsson, Didner & Gerge Fonder AB · Suzanne Sandler, Handelsbanken Fonder AB · Lena Hofsberger, Chair of Ambea AB (publ). Shareholders who wish to submit proposals to the Nomination Committee can do so on the following e-mail address: valberedning@ambea.se or to below address: Ambea ABValberedningenc/o Jacob Persson Box 1565SE-171 29 Solna, Sweden The Nomination Committee’s proposals shall be presented in the convening notice made

Targovax granted European Patent for ONCOS-102 in combination with checkpoint inhibitors

Oslo, 12 October 2020: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announce that the European Patent Office has granted European Patent no 3293201. The patent covers the use of ONCOS-102 in combination with checkpoint inhibitors.Torbjørn Furuseth, Chief Financial Officer of Targovax, said: "We are delighted that this European patent has been granted, further strengthening Targovax's intellectual property portfolio covering the very important combination of ONCOS-102

There are no items matching the current filter
There are no more items matching the current filter
Back to top